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Abstract: Traditional toxicity testing using animal models is slow, low capacity, expensive 
and assesses a limited number of endpoints. Such approaches are inadequate to deal with 
the increasingly large number of compounds found in the environment for which there are 
no toxicity data. Mechanism-centered high-throughput testing represents an alternative 
approach to meet this pressing need but is limited by our current understanding of toxicity 
pathways. Functional toxicogenomics, the global study of the biological function of genes 
on the modulation of the toxic effect of a compound, can play an important role in 
identifying the essential cellular components and pathways involved in toxicity response. 
The combination of the identification of fundamental toxicity pathways and mechanism-
centered targeted assays represents an integrated approach to advance molecular 
toxicology to meet the challenges of toxicity testing in the 21
st century. 
Keywords:  toxicity testing; functional toxicogenomics; toxicity pathways; barcoding; 
yeast 
 
1. Introduction 
Traditional toxicity testing approaches are inadequate to meet the challenge of current toxicity 
assessment requirements. Tens of thousands of chemicals are used annually in industry that have no 
toxicological data associated with them, and this number is ever-increasing [1]. In addition, recent 
advances such as nanotechnology have introduced new classes of compounds into general use that 
represent an additional challenge to risk assessment. Recent initiatives in policy and new 
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developments in toxicology testing are providing the impetus and the means to address this lack of 
knowledge. For example, the recent European Community Regulation REACH (registration, 
evaluation, authorization and restriction of chemicals) will require the registration of ~30,000 chemical 
substances over the next 11 years [2], with a primary aim to progressively substitute the most 
dangerous chemicals with suitable alternatives. Current toxicity testing of chemical compounds is 
based on extensive animal testing, which is time-consuming, expensive and unfeasible for this number 
of compounds. In addition, there is a continuing ethical imperative to reduce the amount of animal 
testing through the 3R’s (“reducing, refining, and replacing”) [3]. Alternative high-throughput 
approaches are clearly needed to meet this need. Animal toxicity tests are also limited in their ability to 
detect toxicity. Only a very limited subset of potential modes of action, as made clear by identification 
of the endocrine disruption activity of some chemicals, is generally assessed. Comprehensive 
mechanistic approaches are needed to assess the diversity of possible modes of toxicity. Functional 
toxicogenomics provides an important tool to identify critical pathways involved in toxicity. 
2. In Vitro Assessment of Toxicity Pathways  
Cell-based high-throughput screens are one aspect of this new mechanistic approach to toxicity 
testing. The number of potentially toxic compounds produced and used both in manufacturing and in 
the pharmaceutical industry requires that new methods be employed to accelerate toxicity testing. The 
changing nature of toxicity testing is highlighted in a 2007 report from the United States National 
Research Council (NRC), entitled Toxicity Testing in the 21
st Century: A Vision and a Strategy [4], 
which outlines a plan to modernize human health toxicity assessment based on the utilization of 
mechanistically-based high-throughput cellular assays [5]. Tox21, a collaborative effort between the 
National Institute of Environmental Health Sciences (NIEHS), the National Human Genome Research 
Institute (NHGRI), the U.S. Environmental Protection Agency (EPA) and recently the U.S. Food and 
Drug Administration (FDA), was established to respond to the NRC challenge to advance the state of 
toxicity testing. The premise of Tox21 is that human harm from chemicals can be inferred from 
activation of toxicity pathways in cells [6]. Toxicity pathways are defined by the NRC as “cellular 
response pathways that, when sufficiently perturbed in an intact animal, are expected to result in 
adverse health effects” [4]. The report did not identify specific toxicity pathways, but a recent review 
has argued that assessment of certain stress response pathways such as oxidative stress, heat shock, 
DNA damage, and endoplasmic reticulum (ER) stress response could be used in cell-based 
toxicological screening [7]. Implementation of a toxicity pathway approach to screening is facilitated 
by the availability of a wide variety of cellular assays developed by academic and commercial 
laboratories for many of these proposed mechanistic endpoints. In addition, many of these assays have 
been adapted for high-throughput screens. For example, the National Institutes of Health Chemical 
Genomics Center (NCGC) is currently screening thousands of compounds as part of Tox21 by 
assessing a wide variety of mechanistic endpoints [8]. Similarly, the EPA’s ToxCast program, started 
in 2006, aims to advance environmental testing by developing methods of prioritizing chemicals for 
further screening and testing to assist EPA programs in the management and regulation of 
environmental contaminants [9]. Phase I of ToxCast has screened a library of 309 chemicals, using 
467 assays, with promising early results [10]. While these in vitro data will provide valuable Int. J. Mol. Sci. 2010, 11                 
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mechanistic insights into the mode of action of potential toxicant compounds, they are limited to 
existing assays of known endpoints. Comprehensive assessment of toxicity will require identification 
of toxicity pathways and development of targeted assays to systematically assess potential modes  
of action.  
3. Toxicogenomics: Omic Tools Applied to Toxicology 
Toxicogenomics can provide insight into the mode of action of toxicants and allow for development 
of targeted cellular assays [11]. Toxicogenomics was defined as “the application of global mRNA, 
protein and metabolite analysis related-technologies to study the effects of hazards on organisms” [12]. 
The underlying premise of toxicogenomics is that a global assessment of the biology of chemical 
exposure can lead to a more thorough understanding of the mechanism of action of toxicants [13]. 
Toxicogenomics studies the interactions between the genome and adverse biological effects caused by 
exogenous agents such as environmental stressors, toxins, drugs and chemicals [14]. 
Toxicogenomics initially arose through the use of microarrays to assess global gene regulation 
(measured by relative abundance of mRNA) following treatment with various stressors (reviewed in 
[15]). One of the aims was to develop “fingerprints” of gene expression changes in response to 
treatment with different classes of known toxicants (oxidant stressors, polycyclic aromatic 
hydrocarbons etc.), which could then be used to gain insight into the mode of action of unknown 
compounds. Expression profiling has been widely used (across many organisms) to discover 
biomarkers for a wide range of toxicants (reviewed in [12–14,16,17]). The data obtained from 
expression profiling can be used to inform selection of mechanism-based assays, such as the NGCG 
assays discussed in the previous section, and thus are an important starting point to the identification of 
toxicity endpoints for cellular assays. However, interpretation and integration of toxicogenomics data 
from a wide range of sources and subsequent mining of these datasets remains a major challenge. 
Currently, several large-scale projects to collect toxicogenomic data and produce minable databases 
are underway, including the Japanese Toxicogenomics Project (TGP) [18], the European Innomed 
PredTox [19], and the Liver Toxicity Biomarker Study [20]. Similarly, other “omics” methodologies 
(e.g., proteomics, metabolomics) are being used to probe toxicity mechanisms and have been reviewed 
extensively elsewhere [12,14,21]. While useful, a limitation is that these omic technologies are 
correlative and do not determine the functional requirement of a gene for the cellular response to a 
toxicant. As a result, there has been extensive discussion of the need for quantifiable “phenotypic 
anchors”, in order to link the patterns of altered gene/protein/metabolite expression to specific 
parameters of well-defined indices of toxicity [22]. Functional toxicogenomics, in contrast to other 
omic approaches, can provide a direct link between gene and toxicant. 
Functional genomics was defined as “the development and application of global (genome-wide or 
system-wide) experimental approaches to assess gene function by making use of information and 
reagents provided by physical mapping and sequencing of genomes” [23]. Functional genomics 
directly measures phenotype, and thus provides a direct link between a specific gene and the 
requirement for that gene product in the cellular response to treatment with a compound [24]. This 
functional information is obtained by screening collections of cells/organisms that lack either genes 
(through deletion) or proteins (through blocking translation by using technologies such as RNAi). Int. J. Mol. Sci. 2010, 11                 
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While conceivably any phenotype could be measured, the viability or fitness of cells or organisms are 
frequently assessed as indicators of alterations in the response to a compound. Recently, the capacity 
of functional genomics to provide an increased mechanistic understanding of toxicant-induced 
phenotypes [12] was recognized and consequently termed functional toxicogenomics. 
4. Functional Toxicogenomics in Yeast 
Functional toxicogenomics is functional genomics in the context of toxicology, i.e., the study of the 
requirement for the biological activities of genes and proteins in the response of, and effect on, an 
organism by a toxicant [12]. In the budding yeast Saccharomyces cerevisiae, global (genome-wide) 
analysis of gene function was initially attempted using different applications of random mutagenesis to 
abolish gene function [25–27]. The sequencing of S. cerevisiae, the first eukaryote genome to be 
sequenced, allowed a directed all-inclusive approach to be taken. All identified genes were 
systematically deleted through a PCR-based approach, using unique 20 bp “barcodes” to disrupt ORFs 
and creating a set of “knockout” yeast strains for both non-essential and essential genes. An important 
consequence of “molecular barcoding” is that multiple deletion strains can be pooled and assayed for 
growth simultaneously (Figure 1).  
Figure 1. Schematic representation of parallel deletion analysis (PDA). PDA quantifies 
the relative abundance of each deletion strain in the pool. Adapted by permission from 
Macmillan Publishers Ltd: Nature Reviews Genetics [28], copyright 2001. 
 
 
Parallel deletion analysis (PDA) is a powerful technique as it allows for quantitative analysis of the 
fitness of every deletion strain tested simultaneously (the so-called “deletome” [29]). In this approach, 
the molecular barcode tags from all strains present in a pooled culture can be amplified simultaneously 
in a single PCR reaction (using a pair of PCR primers that anneal to the common regions flanking the Int. J. Mol. Sci. 2010, 11                 
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inserted barcodes that are present in all strains). These amplified tags can be hybridized to microarrays 
containing oligonucleotides complementary to the barcodes, and the resulting hybridization signal is 
proportional to the number of cells of that strain present when the pooled culture was sampled By 
comparing the hybridization signal of a strain from a culture that has been exposed to a suspected or 
known toxicant (“treatment”) to the signal from the same strain from an untreated culture (“control”), a 
“fitness score” can be derived, and deletion strains whose growth is significantly influenced by the 
treatment compound can be determined [30,31]. If a deletion strain is significantly sensitive to 
treatment, the gene product absent in that strain may be a cellular target of, or may be involved in the 
cellular response to, that treatment compound. The technical aspects of PDA have been described in 
greater detail elsewhere [32–34]. 
This approach was initially used with a small number of deletion strains as a proof of principle [30], 
but was soon expanded to include deletions representing more than one-third of the genome (2026 
ORFs) [35]. This work identified many essential genes (i.e., genes whose deletion cannot be tolerated), 
and an updated disruption method created two barcodes for some ORFs, an UPTAG and a 
DOWNTAG, which can be amplified independently (as opposed to the original single tag). There was 
shown to be good correlation between the two tags [35], and so this feature was adopted in the 
construction of the deletion strain collections currently in use [36]. The 2002 study by Giaever et al 
constructed four different yeast knockout (YKO) collections of strains: one collection of homozygous 
diploid deletions of all non-essential genes (4,757 strains), one of heterozygous diploids   
(5,916–essential and non-essential), and haploid collections of both mating types (4,815 MATa, 4,803 
MAT strains). This study also replaced the printed oligonucleotide arrays used previously with a 
commercially produced custom Affymetrix GeneChip, termed the TAG3 array. This array contained 
oligonucleotides complementary to the UP and DOWNTAG barcodes of every deletion strain. The 
TAG3 arrays were subsequently updated and replaced by TAG4, the array platform currently in use 
[37]. The TAG4 array contains five duplicate sets of probes (replicate features) and data from TAG4 
arrays has been shown to be more reproducible and more accurate when compared with TAG3 [37]. 
To date, functional profiling using the YKO collections and the Affymetrix TAG arrays have been 
used in a number of studies to gain insight into the genetic requirements of the response to several 
compounds and nutritional states (Table 1). The choice of knockout collection used for profiling 
depends on the specific aims of the study being conducted. PDA using the heterozygous collection of 
essential deletions (Haplo Insufficiency Profiling–HIP) can reveal genomic profiles for the cellular 
targets of a drug or toxicant (reviewed in [38]), whereas use of the homozygous collection of non-
essential deletions (HOmozygous deletion Profiling - HOP) can identify genes and pathways that 
buffer the drug or toxicant target pathway [39]. 
The development of high-throughput sequencing technologies has allowed a different method of 
barcode quantification. Termed “Bar-seq” (for Barcode analysis by Sequencing) this analysis relies on 
sequencing of the total amplified barcodes from a pool, rather than detection using a microarray. Initial 
results from Bar-Seq indicate that this approach is superior to microarrays in both dynamic range and 
throughput [40], and it is likely that as sequencing technologies become more affordable, they will 
replace microarrays as the technique of choice for PDA. 
A major contribution of the yeast system has been to provide quantitative phenotypic data to 
validate microarray methods and data modeling procedures [55]. Interestingly, studies in yeast have Int. J. Mol. Sci. 2010, 11                 
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revealed a low correlation between the regulation of a gene’s transcription and its requirement for 
growth under selective conditions [36,56], further suggesting that growth studies such as PDA are a 
better assay to identify genes required for the response to toxicant treatment [53]. However, data from 
expression and functional studies can be integrated to give a greater understanding of the adverse 
effects of toxicant exposure or an altered nutritional state [52]. 
Table 1. Functional toxicogenomics studies in yeast using Affymetrix TAG microarray 
platforms. 
Array 
Platform 
Compound(s) Tested  YKO Collection 
Used 
Reference 
TAG3  High salt; sorbitol; galactose; pH8; minimal 
medium; nystatin 
Homozygous [36] 
TAG3  Glycerol; ethanol; lactate; dinitrophenol  Homozygous  [41] 
TAG3  Alverine citrate; atorvastatin; methotrexate; 5- 
fluorouracil (5-FU); miconazole; amphotericin 
B; lovastatin; cisplatin; itraconazole; 
fluconazole; dyclonine; fenpropimorph 
Heterozygous [42] 
TAG3  None (haploinsufficiency profiling)  Heterozygous  [43] 
TAG3  DNA damaging agents  Homozygous  [44] 
TAG3  ER stressors (tunicamycin; -mercaptoethanol) Homozygous  [45] 
TAG3 Chromium  Heterozygous  [46] 
TAG3 Neurotoxicants  Homozygous  [47] 
TAG3 316  compounds  Homozygous; 
heterozygous 
[48] 
TAG3/4
*  214 psychoactive drugs  Homozygous; 
heterozygous 
[49] 
TAG3  Iron and copper overload  Homozygous  [50] 
TAG4 Imidazo[1,2-a]pyridines and –Pyrimidines  Homozygous; 
heterozygous; 
haploid 
[51] 
TAG3 Iron  deficiency  Homozygous  [52] 
TAG4  Sodium arsenite and monomethylarsonous acid 
(MMA3) 
Homozygous [53] 
TAG4  Methyl methanesulfonate (MMS); cisplatin; 
compound 1561-0023 
Homozygous; 
heterozygous 
[54] 
* Not specified. 
 
S. cerevisiae is a good model for human and higher eukaryote disease and toxicity testing, as yeast 
has functional orthologs of many human disease genes [41,57,58]. Data from fitness screening in yeast 
is therefore informative in the context of the human response to a toxicant, in the cases where there is a 
human ortholog of identified candidate yeast genes whose deletion confers alters sensitivity to a 
compound. PDA has been applied to a number of toxicants, including arsenical compounds [53]. In 
one example, the human ortholog of a gene indentified in the arsenical screen as being required for 
resistance to arsenite in yeast was shown to be required for the resistance of human cells to arsenical Int. J. Mol. Sci. 2010, 11                 
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compounds [59], providing evidence that genes identified by functional profiling in yeast can have 
homologous requirements in human cells.  
The quantitative fitness data from PDA allow for bioinformatic analysis not possible with data from 
qualitative phenotypic screening approaches, such as spotting of strains to microtiter plates and 
assessment of growth by cell density. Network analysis software such as Cytoscape [60] can be used to 
map the fitness data from profiling studies onto a network constructed using known genetic and 
physical interactions between genes and proteins. Analytical tools such as the jActiveModules plug-in 
[61] can then be used to identify functional modules or sub-networks based on fitness data that may 
identify cellular processes or protein complexes affected by toxicant treatment. The extensive study of 
S. cerevisiae has resulted in excellent bioinformatic tools, such as Gene Ontology (GO) annotation 
that, through the use of web-based resources such as FunSpec [62], can be used to identify statistically 
over-represented GO categories within groups of genes (such as those identified as being required for 
tolerance of a toxicant). Human orthologs of yeast genes can be identified using databases such as 
YOGY (eukarYotic OrtholoGY), a powerful database that integrates data to allow identification of 
orthologs across species [63]. These bioinformatic approaches allow identification of functional 
“fingerprints” for compounds, much like expression profiling. Comparison of functional profiles 
between compounds can identify cellular responses and toxicity pathways that are common to multiple 
classes of toxicants. 
A further concept that resulted from functional profiling experiments in yeast has been referred to 
as “combination chemical genetics” or “chemical genomics”. This is defined as “the systematic 
application of multiple chemical or mixed chemical and genetic perturbations, both to gain insight into 
biological systems and to facilitate medical discoveries” [64], and has been covered in a number of 
reviews [33,64–66].  
While primarily concerned with identifying drug targets and undertaking mode of action 
determination, the tools developed for chemical genomics have potential applications in toxicology. 
These tools include novel yeast strain collections, such as the DAmP (decreased abundance by mRNA 
perturbation) collection, which contains hypomorphic alleles of genes (both essential and   
non-essential) [67–69]. The DAmP collection complements the heterozygous deletion collection and in 
some aspects has proven to be more sensitive, identifying several drug targets missed by the HIP assay 
[69]. Another exciting functional technology that may have applications in toxicology is the molecular 
barcoded yeast open reading frame (MoBY-ORF) library [70]. This is a library of barcoded vectors, 
each containing a single yeast gene under the control of its native promoter. There are numerous 
potential applications for this vector library, and so far it has been used in a complementation assay to 
identify genes that when mutated confer drug resistance to cells [70]. Data from assays using these 
various resources will eventually be integrated to improve sensitivity and data quality [71], and these 
approaches could be used in combination to aid the screening of potentially toxic compounds. Recent 
work undertaken to uncover interactions between genes through synthetic lethality (by generating 
libraries of double mutants) has produced extensive interaction networks [72], which may help to 
elucidate toxicity pathways in yeast and help to determine the mode of action of test compounds when 
integrated with data from functional screens. 
Although functional screening in yeast is a powerful tool for helping to establish the toxicity of 
compounds, and for identification of conserved cellular processes required for sensitivity or tolerance Int. J. Mol. Sci. 2010, 11                 
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to tested compounds, there are limitations of the yeast system. As a eukaryote S. cerevisiae is an 
excellent model organism for studying fundamental cellular processes but it is not an accurate 
indicator for determination of the toxic dose of a compound for human exposure, as in general S. 
cerevisiae is able to tolerate much higher doses of toxicants than human cells [53]. There are however 
other deficiencies with the yeast system. Clearly yeast cannot provide data on organ or tissue-specific 
toxicity and being unicellular, no insight into the roles of cell-cell signaling, such as endocrine 
disruption, by a compound can be deduced using this system. The great evolutionary distance between 
yeast and humans is also an issue. Although many yeast genes have functional orthologs in humans, 
many yeast genes have human homologs that encode proteins whose function is not conserved. 
Conversely there may be human orthologs of candidate yeast genes that cannot be determined using 
bioinformatics due to excessive sequence divergence of either the gene or protein encoded. A similar 
confounding factor that hinders the identification of human orthologs of yeast susceptibility genes is 
the presence in humans (and other higher eukaryotes) of gene families. Due to this, single yeast genes 
can have a large number of equally probable human orthologs, and it is at present impossible to predict 
which (if any) are the true human ortholog(s) of the yeast gene without experimentation. In order to 
address these issues, similar functional toxicogenomics technologies are now being developed in 
higher eukaryotic systems.  
5. Functional Toxicogenomics in Higher Eukaryotes 
Development of functional genomics in higher eukaryotic systems has been more challenging than 
in yeast, primarily due to the difficulty of creating homozygous gene knockouts in mammalian cells. 
Although techniques for gene disruption in mammalian cells have advanced, it is still time-consuming 
and expensive, and so creating a library of deletion cell lines similar to the yeast collections is not 
practical at this time. Small collections of targeted knockout cell lines have been produced in chicken 
DT40 cells, and are being used to study compounds such as formaldehyde [73], but there are no such 
targeted deletions yet available for mammalian cell lines. 
Functional genomics in mammalian systems has been made possible by RNA interference (RNAi). 
RNAi works by targeting the expressed mRNA of a gene and preventing translation, effectively 
“knocking down” the function of the targeted gene. RNAi was first discovered in the nematode 
Caenorhabditis elegans [74], and has since been developed for use in many other organisms. The 
application of genome-wide RNAi has become an integral functional genomic tool for drug target 
identification and validation, pathway analysis and drug discovery [75], and can readily be applied to 
toxicology. Loss-of-function genetic screens using RNAi in human cell lines can be carried out in a 
high-throughput manner and, as a consequence of the functional nature of the approach, can lead to the 
identification of causal factors, as in yeast [76]. High-throughput RNAi (HT-RNAi) screening can be 
conducted using two different methods of RNAi, either using short hairpin RNA (shRNA) vector 
libraries (reviewed in [76]), or using chemically or enzymatically generated small interference RNAs 
(siRNA-reviewed in [75]).  
shRNA screening (referred to as shRNA bar coding) uses vector libraries such as The RNAi 
Consortium (TRC) lentiviral library, which contains shRNAs targeting 17,200 humans genes [77]. 
Each shRNA is identifiable by a unique bar code, much like the yeast deletion collections. The bar Int. J. Mol. Sci. 2010, 11                 
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code in shRNA libraries can be a separate DNA sequence in the plasmid vector, or it can be part of the 
shRNA cassette. shRNA bar code screening allows identification of shRNAs that give rise to a specific 
phenotype under the conditions of toxicant treatment. Cells from the cell line of choice are infected in 
sufficient numbers to ensure that the whole vector library is represented. Two replicate populations 
(pools) of cells are created, one untreated control and one pool treated with the test compound. Cells 
are then grown in petri dishes, and bar codes are recovered by PCR. Bar codes can then be hybridized 
to microarrays, similar to the yeast system, in order to quantify the abundance of shRNAs in both the 
control and treatment populations. Relative abundance of shRNAs can then be determined to identify 
those that are affected by the treatment compound. shRNA bar coding is very effective at identifying 
genes whose knockdown increases fitness under test conditions, and has been successfully applied to 
find genes whose inactivation play a role in cancer progression (reviewed in [76]). The detection of a 
decrease in shRNAs (equivalent to identifying sensitive yeast deletion strains) is more challenging, but 
has recently been achieved [78]. It is also possible to conduct shRNA screens using vectors that do not 
contain bar codes. In this case, shRNAs are recovered from a population of cells resistant to test 
compound treatment and are sequenced to identify the knocked down gene(s) [79]. 
siRNA cannot be used in this manner. In siRNA screening, cells are grown in microplates and a 
single siRNA is added to each well (single well screening). Cells can then be assayed using a variety 
of methods, including high content microscopy or viability screening, or through a number of different 
reporter assays (reviewed in [80]). 
As previously mentioned, RNAi has been used extensively in other eukaryotes. RNAi screening is 
perhaps best characterized in C. elegans (reviewed in [81]) and has been used in toxicological studies 
[82]. It is also used extensively in the fruit fly Drosophila melanogaster (reviewed in [83]). In 
addition, RNAi screening is now possible in zebrafish, and has the potential to be extremely useful in 
environmental toxicity testing [84]. An advantage of these whole organism systems over cells in 
culture is that aspects such as developmental toxicology and endocrine disruption can be studied, as 
well as organ specificity of toxicity.  
RNAi does, however, have some limitations as a functional screening tool. Two major issues that 
affect all applications of RNAi are the incomplete knockdown of target genes and off-target effects 
(the knockdown of genes other than the target). A recently developed functional screening technology 
that is not affected by these issues uses a human chronic myeloid leukemia (CML) cell line that is 
haploid for all but one chromosome [85]. Insertional mutagenesis was used to generate a population of 
cells carrying heterogeneous null mutations of genes. Mutagenized cells can then be cultured in wells 
of a microplate in the presence of the test compound. Cells with increased resistance to the test 
compound due to a null mutation form colonies after extended incubation, and the insertion 
responsible for the mutation can be mapped using a PCR-based technique. This approach has been 
successfully used to identify host factors used by pathogens [85], and will likely be used extensively in 
the future for toxicity testing. 
To date, functional screens have been conducted using a number of higher eukaryotic systems 
(Table 2). In human cell systems functional screening has predominantly been used for direct medical 
applications such as cancer studies, and for some drug development. As use of these technologies 
becomes more widespread, it is expected that there will be a significant increase in the use of these Int. J. Mol. Sci. 2010, 11                 
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technologies in toxicology, in order to provide functional data on the roles of human genes in 
modulating the toxicity of chemical compounds.  
Table 2. Selected functional genomics studies in higher organism systems. 
System (organism)  Outcome  Reference 
shRNA bar code (human)  Identification of genes whose suppression confers 
resistance to p53-induced growth arrest 
[86] 
shRNA bar code (human)  Identification of genes whose suppression confers 
resistance to p53-induced growth arrest 
[87] 
shRNA bar code (human)  Identification of genes whose suppression confers 
resistance to Herceptin 
[88] 
siRNA (human)  Identification of genes required for paclitaxel 
tolerance 
[89] 
RNAi (C. elegans)  Identification of genes involved in the toxicogenesis 
of a polychlorinated biphenyl (PCB) 
[82] 
shRNA (human)  Identification of radiation susceptibility genes  [90] 
siRNA (human)  Identification of genes required for stress resistance  [91] 
shRNA bar code (human)  Identification of genes required for cancer 
proliferation 
[92] 
shRNA (human)  Identification of genes required for induction of 
apoptosis 
[79] 
RNAi (zebrafish)  Characterization of novel human platelet proteins  [93] 
siRNA (human)  Identification of genes whose suppression confers 
resistance to epirubicin 
[94] 
Mutagenized haploid cells 
(human) 
Identification of diptheria toxin pathway genes  [85] 
RNAi (D. melanogaster)  Identification of modifiers of mutant Huntingtin 
aggregate formation 
[95] 
6. Integrating Functional Data to Identify Toxicity Pathways Will Lead to Comprehensive 
Cellular Assays  
Current high-throughput assays focus on well-characterized cellular response pathways to toxicity. 
Functional toxicogenomics is a powerful technique that can identify currently unknown or 
unappreciated genetic modulators of chemical toxicity. Computational approaches such as clustering 
can identify shared gene and pathway requirements for different toxicants. The functional information 
can subsequently be integrated with existing annotation and high-throughput data through network 
representation software such as Cytoscape [60]. Analysis of existing networks can identify key genes 
in cellular response pathways (“hubs”) to toxicity. Selection of high-throughput assays for use in 
toxicity testing could then be driven by the capability to assess induction or disruption of these “hubs”. 
For example, a recent analysis of functional genomic data in yeast identified defects in vesicle 
tethering complexes as conferring sensitivity to particular toxicants [96]. Similarly, we recently found 
that genes modulating histone acetylation may play a role in arsenic toxicity [59]. High-throughput 
assays could be developed to assess effects on both of these processes. In addition to the identification 
of a role for existing pathways, network inference or reverse engineering methods (that have generally Int. J. Mol. Sci. 2010, 11                 
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focused on gene expression, but that could be applied to quantitative functional data) could identify 
novel cellular pathways and processes that are required for both the response to, and the induction of, 
toxicity.  
We suggest that data from functional toxicogenomics studies in yeast and other organisms can be 
used in conjunction with data from other sources (such as expression profiling of exposed human 
populations) to provide a “systems biology” approach to studying the toxicity of compounds [97]. 
Functional toxicogenomics can be used to define both novel and more specific toxicological endpoints, 
and inform the choice of assays used in high-throughput screening. Functional toxicogenomics is 
therefore a vital tool in advancing molecular toxicology, forming part of an integrated approach to 
meet the challenges of 21
st century toxicity testing. 
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